Image source: Getty Images.Rigel Pharmaceuticals (NASDAQ: RIGL) is down 23% at 11:30 a.m. EDT after the company reported a second phase 3 clinical trial testing for its spleen tyrosine kinase inhibitor, fostamatinib, in patients with adult chronic/persistent immune thrombocytopenia failed to live up to the results of the first trial.Continue reading